Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rafah Salloum

Rheumatology Manalapan, NJ Medical Doctor

NPI 1457417040 CMS profile 338654

219 Taylors Mills Rd, Manalapan, NJ 07726

Open in the dashboard

General payments

$8,516

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rafah Salloum of Manalapan, NJ is reported in the CMS Open Payments database as having received $8,516 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,353 59
2024 General $1,361 68
2023 General $1,241 55
2022 General $1,484 58
2021 General $1,023 57
2020 General $845 49
2019 General $1,209 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rafah Salloum
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Rafah Salloum were reported at $1,353. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Rafah Salloum Rheumatology median Middle half National median
2019 $1,209 $744 $153–$2,687 $163
2020 $845 $462 $98–$2,027 $114
2021 $1,023 $531 $101–$2,153 $132
2022 $1,484 $627 $125–$2,303 $149
2023 $1,241 $741 $145–$2,524 $160
2024 $1,361 $830 $166–$2,660 $164
2025 $1,353 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,061 140 payments
  2. Amgen Inc. $1,122 72 payments
  3. Janssen Biotech, Inc. $1,106 59 payments
  4. AstraZeneca Pharmaceuticals LP $1,096 21 payments
  5. Janssen Pharmaceuticals, Inc $587 6 payments
  6. Novartis Pharmaceuticals Corporation $458 20 payments
  7. Mallinckrodt Hospital Products Inc. $314 13 payments
  8. Pfizer Inc. $233 15 payments
  9. Janssen Scientific Affairs, LLC $228 2 payments
  10. UCB, Inc. $226 10 payments
  11. Other $1,086 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,203 416 payments
  2. Education $313 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,375 95 payments
  2. TREMFYA $1,044 50 payments
  3. XARELTO $815 8 payments
  4. SAPHNELO $527 14 payments
  5. HUMIRA $359 22 payments
  6. Prolia $349 26 payments
  7. Otezla $333 15 payments
  8. SKYRIZI $313 22 payments
  9. COSENTYX $300 15 payments
  10. Enbrel $294 20 payments
  11. Other $3,926 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,397

Median for Rheumatology: 1,511

Drug cost

$676,326

Median for Rheumatology: $1,139,948

Branded share of claims

35.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 39 $278,370
Rinvoq Upadacitinib Brand 17 $103,888
Actemra Actpen Tocilizumab Brand 22 $103,466
Orencia Clickject Abatacept Brand 13 $71,343
Otezla Apremilast Brand 13 $62,283
Tymlos Abaloparatide Brand 11 $33,476
Methotrexate Methotrexate Sodium Brand 380 $7,430
Hydroxychloroquine Sulfate Generic 195 $7,312
Leflunomide Generic 92 $3,490
Alendronate Sodium Generic 221 $2,118

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$106,722

Of which drugs: $3,338

Medicare patients

276

Average age 75

Services billed

8,200

218 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 46%
Ischemic heart disease 30%
Diabetes 21%
Depression 20%
Chronic kidney disease 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 54 6,601 $666
Injection, methylprednisolone acetate, 40 mg J1030 Office 27 44 $200

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $412
$412 — —
RINVOQ
  • AbbVie, Inc. $408
$408 17 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $92
$92 — —
SKYRIZI
  • AbbVie, Inc. $74
$74 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record